ReviewToxins2012
Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals.
Review in Toxins, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 143 citations in OpenAlex.
- Antibody Screening and Binding Prediction Analysis Targeting Stx2.Antibodies (Basel, Switzerland) · 2026Article
- External factors influence intrinsic differences in Stx2e production by Porcine Shiga Toxin-producing Escherichia coli strains.PLoS pathogens · 2025Article
- Shiga Toxin Type 2 Aggravates G1/S Phase Cell Cycle Arrest, Mediating Caspase-Independent Cell Death under Hyperosmotic Conditions in the Kidney.Journal of microbiology and biotechnology · 2025Article
- Curcumin Reverses Antibiotic Resistance and Downregulates Shiga Toxin Expression in EnterohemorrhagicDiseases (Basel, Switzerland) · 2025Article
- Article
- Impact of Metabolites from Foodborne Pathogens on Cancer.Foods (Basel, Switzerland) · 2024Review
- Human Gb3/CD77 synthase: a glycosyltransferase at the crossroads of immunohematology, toxicology, and cancer research.Cellular & molecular biology letters · 2024Review
- Prevalence and Characteristics of Plasmid-Encoded Serine Protease EspP in Clinical Shiga Toxin-ProducingMicroorganisms · 2024Article
- A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy.Antimicrobial agents and chemotherapy · 2024Article
- Article
- Article
- Cardiovascular impairment in Shiga-toxin-2-induced experimental hemolytic-uremic syndrome: a pilot study.Frontiers in immunology · 2023Article
- Oral Administration with Live Attenuated Citrobacter rodentium Protects Immunocompromised Mice from Lethal Infection.Infection and immunity · 2022Article
- EnterohemorrhagicInternational journal of molecular sciences · 2022Review
- Intestinal Enteroid Monolayers Model the Human Intestinal Environment for Escherichia coli Infection.Journal of bacteriology · 2022Article
- Thrombotic microangiopathies: An illustrated review.Research and practice in thrombosis and haemostasis · 2022Review
- Article
- Intestinal Organoids: New Tools to Comprehend the Virulence of Bacterial Foodborne Pathogens.Foods (Basel, Switzerland) · 2022Review
- Antimicrobial Resistance, Serologic and Molecular Characterization ofAntibiotics (Basel, Switzerland) · 2021Article
- Prevalence of genotypic antimicrobial resistance in clinical Shiga toxin-producingJournal of medical microbiology · 2021Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Food-borne diseases are estimated at 76 million illnesses and 5000 deaths every year in the United States with the greatest burden on young children, the elderly and immunocompromised populations. The impact of efficient food distribution systems and a truly global food supply ensures that outbreaks, previously sporadic and contained locally, are far more widespread and emerging pathogens have far more frequent infection opportunities. Enterohemorrhagic E. coli is an emerging food- and water-borne pathogen family whose Shiga-like toxins induce painful hemorrhagic colitis with potentially lethal complications of hemolytic uremic syndrome (HUS). The clinical manifestations of Shiga toxin-induced HUS overlap with other related syndromes yet molecular mechanisms differ considerably. As discussed herein, understanding these differences and the novel properties of the toxins is imperative for clinical management decisions, design of appropriate animal models, and choices of adjunctive therapeutics. The emergence of new strains with rapidly aggressive virulence makes clinical and research initiatives in this field a high public health priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.